FOXO3 Encodes a Carcinogen-Activated Transcription Factor Frequently Deleted in Early-Stage Lung Adenocarcinoma

Oliver R. Mikse, Daniel C. Blake, Jr., Nathan R. Jones, Yuan-Wan Sun, Shantu Amin, Carla J. Gallagher, Philip Lazarus, Judith Weisz, and Christopher R. Herzog

Abstract

The FOXO family of transcription factors elicits cell cycle arrest, apoptosis, and resistance to various physiologic and pathologic stresses relevant to sporadic cancer, such as DNA damage and oxidative stress. Although implicated as tumor suppressors, FOXO genetic inactivation has not been observed in human cancer. In an investigation of the two major types of non–small cell lung cancer, here, we identify the FOXO3 gene as a novel target of deletion in human lung adenocarcinoma (LAC). Biallelic or homozygous deletion (HD) of FOXO3 was detected in 8 of 33 (24.2%) mostly early-stage LAC of smokers. Another 60.6% of these tumors had losses of FOXO3 not reaching the level of HD (hereafter referred to as sub-HD). In contrast, no HD of FOXO3 was observed in 19 lung squamous cell carcinoma. Consistent with the deletion of FOXO3 were corresponding decreases in its mRNA and protein levels in LAC. The potential role of FOXO3 loss in LAC was also investigated. The carcinogen (+)-anti-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene (BPDE) is strongly implicated as a cause of human lung cancer. Here, we show that FOXO3a is functionally activated and augments the level of caspase-dependent apoptosis in cells exposed to this DNA-damaging carcinogen. These results implicate FOXO3 as a suppressor of LAC carcinogenesis, a role frequently lost through gene deletion. Cancer Res; 70(15); OF1–11. ©2010 AACR.

Introduction

Lung cancer exceeds all cancer types as the leading cause of cancer death worldwide (1). Eighty-seven percent of these cases are classified as non–small cell lung cancer (NSCLC), among which lung adenocarcinoma (LAC) and lung squamous cell carcinoma (LSqCC) are major histotypes (1). The majority of lung cancer is causally linked to chronic exposure to air-borne carcinogens (2–4). In particular, epidemiologic and experimental studies together have established that carcinogens present in cigarette smoke account for ~85% of all human lung cancer (2–4).

LAC and LSqCC develop through distinct pathogenetic pathways, and they respond differently to treatment (5, 6). Another level of complexity to the underlying biology of these tumors is that those of smokers and never smokers also have some distinct molecular and clinical characteristics and as such can be viewed as separate diseases (7). Compared with LACs, LSqCCs tend to have higher incidences of TP53 inactivation and allelic losses on chromosomes 13q14 (RB), 9p21 (p16INK4a), 8p21-23, and several regions of 3p (reviewed in refs. 5, 6). In LAC, mutations of K-ras, epidermal growth factor receptor (EGFR), and Her2/neu and allelic losses on 6q and 19p are more typical (8–12). Comprehensive genome-wide studies have also revealed many unidentified genes that are recurrently altered in and, therefore, are likely to contribute in some way to the development of these tumor types (13–15). The identification and characterization of these unknown participants should further our understanding of NSCLC and, ultimately, lead to improved therapies.

Functions that contribute to the inhibition or suppression of cancer are often selectively inactivated in tumors by gene deletion. This can occur as a consequence of any of several errors in chromosome maintenance, such as mitotic recombination, mitotic nondisjunction, chromosomal breakage, or rearrangement (16–19). Quantitative PCR (qPCR) is a validated tool to quantify the relative copy number of specific DNA sequences that result from these defects (20–23). With the availability of highly dense databases of the annotated human and mouse genomes, PCR now essentially has single-nucleotide resolution for detecting genetic targets of copy number changes. We recently showed by qPCR that FOXO3 is deleted in carcinogen-induced LAC of mice and in human NSCLC cell lines (24, 25). This suggests that FOXO3 loss contributes to NSCLC pathogenesis.

The proposition that FOXO3 is a "tumor suppressor" is supported by several lines of evidence. FOXO3 is one of four related FOXO transcription factors that protect cells against...
a wide range of physiologic stresses (26). In particular, FOXO3 has been shown to play a role in DNA repair, growth arrest, and apoptosis in response to DNA damage and oxidative stress (26–29). We recently showed that FOXO3 activates a proapoptotic transcription program and cellular response to the human lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK; ref. 25). FOXOs are negatively regulated at the protein level by the serine/threonine kinase, Akt (26, 31–33). Akt phosphorylates FOXOs on specific residues that promote 14-3-3 binding and results in its cytosolic retention and transcriptional inactivation (31–33). Akt is activated by EGFR—phosphatidylinositol 3-kinase (PI3K) signaling, a pathway frequently upregulated in NSCLC (5, 10). Under certain stress conditions, the negative control of FOXOs by Akt is overcome through both phosphorylation and acetylation of FOXOs, which results in their transcriptional activation (reviewed in refs. 26, 34). Finally, the tumor suppressor roles of FOXOs have been confirmed in mice, where it was shown that germline inactivation of Foxo1, Foxo3, and Foxo4 (Foxo6 was not examined) predisposed mice to lineage-specific tumorigenesis (35). Here, we show that FOXO3 is selectively deleted in human LAC. We also show that FOXO3 is functionally activated by and elicits a proapoptotic response to (+)-anti-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene (BPDE), a human lung carcinogen. The findings of this study implicate FOXO3 as an anticarcinogenic suppressor of LAC.

Materials and Methods

Tissues and cell lines

Human lung tissues were obtained from the tumor and tissue bank of the Penn State Cancer Institute (Institutional Review Board protocols 24072EP and 29448EP). Tumor stage was assigned using standard tumor-node-metastasis criteria. Normal lung tissue was obtained from the Sun Health Research Institute’s Brain and Body Donation Program for which the autopsy results showed normal lungs. Samples were excluded for any type of abnormality, including gross and microscopic abnormalities such as bronchopneumonia, lung cancer, or metastatic cancer. The majority of the tumors, both LAC and LSqCC, examined in this study were early-stage carcinoma (see Fig. 1D for the stage of each of the tumors examined in this study). Genomic DNA was isolated from frozen patient samples using previously published methods (20). H358, A549, and H1299 cell lines were obtained from the American Type Culture Collection. All cell lines were grown in RPMI 1640 supplemented with 10% fetal bovine serum, 2 mmol/L glutamine, 100 μg/mL penicillin, and 100 mg/mL streptomycin in a humidified incubator at 37°C, 20% O2, and 5% CO2.

Deletion analysis

Gene deletions were determined by qPCR of genomic DNA, as previously reported (20, 24). PCR was carried out as follows: 95°C for 2 minutes followed by 22 to 25 cycles (i.e., within exponential phase) at 95°C, 55°C to 60°C, and 72°C each for 30 seconds. PCR products were resolved in 2% agarose gels stained with ethidium bromide. Deletions were determined by calculating target intensity/control intensity in the tumors and cell lines divided by that value obtained from normal DNA. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-actin were used as controls. Several primer pairs were used in the deletion analysis of FOXO3 and its flanking genes, ARMC2 and LACE1. Primers for FOXO3 used in this study are listed in Table 1. Additional primer pairs used include (5′-3′) ARMC2-1 (forward, ATACACTCTGCGAAGGAGGTGCT; reverse, TGTCGAGCTTCTGTTTCCCTCCGT), LACE1-1 (forward, GTGTCGAACAGCCACAGGGCA; reverse, TGCTGCAAGGAGCAAGTGTCTA), β-actin (forward, GCACACACTTCTACAATGAG; reverse, CCTCATGAGTACTGAGTCAGG), GAPDH (forward, GTATTGGCCGCTGTGTCACC; reverse, CAGTGGACTCCACGACGTAC), FOXO1 (forward, TATGAAACCGCTGACCACAGTGAA; reverse, TGCCGGTTCTGTGAGGTGGA), and FOXO4 (forward, AGTTCACATGCCCAGTCTGAGC; reverse, TGCTGCAAAGAGCCAGAGAGA). Primers used were designed based on the available gene sequences from National Center for Biotechnology Information (NCBI) and Ensembl genome browsers and purchased from Integrated DNA Technologies. Oligos were designed to avoid known single-nucleotide polymorphisms that may affect gene dose quantitation.

Quantification was carried out by densitometry using UVP Imaging and Analysis System and LabWorks software (UVP, Inc.). Gene dose was quantified as follows: test gene intensity/control gene intensity of tumor DNA divided by that of normal (noncancerous) tissue DNA as previously described (24). To account for genetic and cellular heterogeneity of the tumor samples, gene homozygous deletion (HD) was defined as a reproducible gene dose reduction of ≥80% relative to normal DNA. A gene reduction of 40% to 80% relative to control levels was considered a hemizygous or subclonal homozygous loss. For deletion scoring, a minimum of two contiguous, nonoverlapping PCR products within FOXO3 must have met the threshold of HD or sub-HD. The approximate locations of the FOXO3 primers used are shown in Table 1 and Fig. 1B.

Mutation analysis

Examination of tumors and cell lines for mutations within the coding region of human FOXO3 (i.e., exons 2 and 3) was carried out by direct sequence analysis of PCR-amplified fragments. Sequencing was performed by the Genomics Core Facility of the Penn State University using an ABI Hitachi 3730XL DNA Analyzer using protocols provided by the manufacturer.

RNA extraction and cDNA synthesis

Total RNA was extracted from tissue samples using RNeasy Mini kit (Qiagen) according to the manufacturer’s protocol. Samples were subjected to on-column DNase I digestion during extraction to prevent confounding of the results by genomic DNA contamination. RNA concentrations were determined using a NanoDrop ND-1000 spectrophotometer, and RNA purity was assessed by absorbance ratios.
A_{260/A_{280}} (>1.9) and A_{260/A_{230}} (>1.8). Reverse transcription was performed using SuperScript First-Strand cDNA Synthesis kit (Invitrogen) with 1 μg of starting RNA per sample. A negative control without RNA and a negative control without enzyme were analyzed in parallel.

Real-time quantitative reverse transcription-PCR
FOXO3 expression in lung tissue was assessed using Taqman gene expression assays (Applied Biosystems). Expression levels were normalized to GAPDH content. cDNAs were run in quadruplicate and amplified in a 10 μL reaction

Table 1. FOXO3a qPCR primers

<table>
<thead>
<tr>
<th>Name</th>
<th>Forward</th>
<th>Reverse</th>
<th>Length</th>
<th>Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>FOXO3a set 1</td>
<td>CGGGCAGCCGAGAAATGTT</td>
<td>TGTTGCTGTCGCCTTATCCTT</td>
<td>172 bp</td>
<td>n555–727 exon 2</td>
</tr>
<tr>
<td>FOXO3a set 2</td>
<td>AGATCTACAGTGAGTGATTCGTT</td>
<td>AAGCAGATCCTCGAGGAATCCGAGA</td>
<td>168 bp</td>
<td>n686 exon 2–n86 introns 2–3</td>
</tr>
<tr>
<td>FOXO3a set 3</td>
<td>TCTCGGATTCGTCGGAGTCGTT</td>
<td>TCCAGGAAATGTCGCTGCGCTC</td>
<td>207 bp</td>
<td>n86–282 introns 2–3</td>
</tr>
<tr>
<td>FOXO3a set 4</td>
<td>TGGATGCGGACATGCGGGGAGGAGA</td>
<td>TGGATCGGAGTGATGCTGCGCTGCA</td>
<td>281 bp</td>
<td>n768–1049 introns 2–3</td>
</tr>
<tr>
<td>FOXO3a set 5</td>
<td>TGACGATATGGCAGCACTGGAGAT</td>
<td>TTCTCTTGGATGATGCTGCGCTGCA</td>
<td>232 bp</td>
<td>n508–740 exon 3</td>
</tr>
<tr>
<td>FOXO3a set 6</td>
<td>AAGTGAGCCATGAGGAGCACCAGATG</td>
<td>TGCTGTCGCTCCTTTATATCTGGA</td>
<td>558 bp</td>
<td>n166–724 exon 2</td>
</tr>
<tr>
<td>FOXO3a set 7</td>
<td>AAGATGTCAGCGAGGCCGCGGTT</td>
<td>AAGCAGATCCTCGAGGAATCCGAGA</td>
<td>710 bp</td>
<td>n142–n86 introns 2–3</td>
</tr>
</tbody>
</table>

Figure 1. FOXO3 deletions in human NSCLC. A, diagrammatic representation of the human FOXO3 locus. B, relative locations of the FOXO3 sequences analyzed by qPCR. C, representative qPCR analysis of LAC DNA showing deletions within FOXO3. D, summary of qPCR data of FOXO3 and flanking genes. Values shown are gene doses in tumors relative to normal DNA normalized with either GAPDH or β-ACTIN. Values are the means of several experiments, which resulted in minimal SD. Black, HD; dark gray, sub-HD DNA loss in the range of 60% to 79% decrease; light gray, sub-HD DNA loss in the range of 40% to 59% decrease; white, no DNA loss.
at a concentration of 15 μM. A pan-caspase inhibitor Z-VAD-FMK (Sigma-Aldrich) was used for 1 hour following transfection. Twenty-four hours following transfection, cells were plated in selective medium (containing 5 μg/mL of G418). MTS assays were carried out according to the manufacturer’s recommendations (Promega) to determine the extent of cell death caused by these treatments. Cells treated with BPDE were also collected at the indicated time points for Western blot analysis, as described below. The extent of cell death caused by these treatments was determined by calculating target PCR intensity/control PCR intensity of the sample minus the ΔCt value of a calibrator sample, in this case the highest expressing adjacent normal tissue. Relative quantification was then determined with the formula 2^(-ΔΔCt). FOXO3 mRNA expression was also analyzed by normalization to three additional control genes: RPLP0, HPRT1, and PES1. These genes were found to be stably expressed in a subset of matched lung tumor and adjacent normal samples (data not shown).

For qPCR data, statistical analyses were done using GraphPad Prism version 5.00. Expression of FOXO3 in matched tumor and adjacent normal tissue was compared using the Wilcoxon signed rank test with significant P value of <0.05.

Transfections and treatment of cells
Expression vector of FOXO3 cDNA was generated from RNA isolated from human buccal cells. Reverse transcription was carried out on 1 μg of total RNA using 200 units of Moloney murine leukemia virus (MMLV) reverse transcriptase for 1 hour at 37°C. High-fidelity PCR amplification of full-length FOXO3 cDNA used Hi-Fi Platinum Taq DNA polymerase (Invitrogen). Amplified FOXO3 cDNA was cloned into the pcDNA3 mammalian expression vector (Invitrogen), and wild-type clones were confirmed by direct sequence analysis. Transfections of A549 and H358 cells were carried out using Lipofectamine reagent (Invitrogen), with conditions optimized for 1 μg of plasmid DNA in 35-mm2 dishes. Cells (1 × 10^6) were seeded into six-well plates (35 mm^2 per well) for transfection. Cells were treated with BPDE (0.4–0.7 μmol/L) for 1 hour following transfection. Twenty-four hours following transfection, cells were plated in selective medium (containing G418). MTS assays were carried out according to the manufacturer’s recommendations (Promega) to determine the extent of cell death caused by these treatments. Cells treated with BPDE were also collected at the indicated time points for Western blot analysis, as described below. The pan-caspase inhibitor Z-VAD-FMK (Sigma-Aldrich) was used at a concentration of 15 μmol/L. Treatment with the inhibitor commenced 1 hour before treatment with BPDE.

Reverse transcription-PCR
RNA was isolated using Trizol reagent and subjected to reverse transcription with MMLV reverse transcriptase. PCR was performed on 50 to 100 ng of high-quality cDNA to determine the expression levels of reported FOXO3 effector genes. This was carried out essentially as described above for deletion analysis. Quantitation of target genes was determined by calculating target PCR intensity/control PCR intensity in the test (treated) sample relative to that of the control (untreated) sample. GAPDH and β-ACTIN were used as control genes for test gene expression quantitation. Quantification was carried out by densitometry using UVP Imaging and Analysis System and LabWorks software. Oligonucleotide primers used in this study were designed based on the available gene sequences from NCBI and Ensembl genome browsers and purchased from Integrated DNA Technologies.

Immunocytochemistry
Formalin-fixed, paraffin-embedded human lung tissue was sectioned at 5 μm and placed on glass slides. A low-temperature antigen retrieval procedure was applied to deparaffinized and rehydrated tissue sections using Antigen Unmasking Solution (Vector Laboratories) at low pH for 1 hour at 80°C. Immunocytochemistry was performed using rabbit monoclonal primary antibody to FOXO3a (Epitomics) diluted 1:50 and incubated overnight at 4°C. The ImmPRESS polymerized reporter enzyme staining system for rabbit antibodies was used (Vector Laboratories). ImmPACT DAB (Vector Laboratories) was used as the chromogen followed by Vector Methyl Green counterstain (Vector Laboratories) or a blush of Eosin Y/Phloxine (Sigma-Aldrich) to visualize cytoplasm. Endogenous peroxidase was inhibited by treating the sections with hydrogen peroxide. Negative control slides were immunostained in the absence of primary antibody. A set of slides matching those stained for FOXO3 was also stained with H&E (Supplementary Fig. S1).

Immunofluorescence
H1299 cells were grown on chamber slides in completed RPMI 1640. At ~50% confluence, the cells were synchronized with 1 mmol/L hydroxyurea in completed medium for 12 hours. Cells were washed twice with culture medium and treated with 0.7 μmol/L BPDE in the same medium for 2, 4, and 8 hours. Cells were fixed with 4% paraformaldehyde for 10 minutes on ice, washed, and permeabilized with PBS/0.02% Triton X-100 and then blocked with PBS/3% bovine serum albumin (BSA). Primary FOXO3 (H-144) and 14-3-3 γ antibodies (Jackson Immunoresearch Laboratories) were applied overnight at 4°C; Cy5- and Cy3-conjugated and Cy5 secondary antibodies (Jackson Immunoresearch Laboratories) were applied following washing at a concentration of 10 μg/mL and incubated overnight at 4°C. Cy5- and Cy3-conjugated and Cy5 secondary antibodies (Jackson Immunoresearch Laboratories) were applied following washing at a concentration of 10 μg/mL and incubated at room temperature for 2 hours. Nuclei were stained with Hoescht stain at a dilution of 1:10 for 1 hour at room temperature. Images were acquired with a Leica confocal microscope (TCS SP2 AOS, Leica Microsystems) using a 488-nm laser for the Cy2, a 543-nm laser for the Cy3, and 633-nm laser for the Cy5 fluorophores. The fluorophores were imaged using a sequential line scan, with detection bands set at 420 to 475 nm for Hoescht stain and 554 to 640 for Cy3. Each image was saved at a resolution of 1,024 × 1,024 pixel image size. The optical sections were reconstructed by maximum projection with the Leica software. This work was done in collaboration with the Microscopy Core Facility at the Pennsylvania State University College of Medicine.

Western blotting
Typically, 25 to 40 μg of whole-cell lysates were denatured in 1× Laemmli sample buffer, electrophoresed, and transferred...
Secondary antibodies were conjugated with horseradish peroxidase and used at a dilution of 1:500 (Santa Cruz Biotechnology). Rabbit polyclonal anti-FOXO3 (1:3,000, Sigma-Aldrich). Antibodies used and their sources and concentrations were as follows: mouse monoclonal anti-FOXO3 (H-144) was used at a dilution of 1:500 (Stressgen). Rabbit polyclonal anti-FOXO3 (H-144) was used at a dilution of 1:3,000 (Sigma-Aldrich). Antibodies used and their sources and concentrations were as follows: mouse monoclonal anti-caspase-7, anti-caspase-8, and anti-caspase-9 were used at dilutions of 1:500 (Stressgen). Rabbit polyclonal anti-α-tubulin was used at a dilution of 1:500 (Santa Cruz Biotechnology). Secondary antibodies were conjugated with horseradish peroxidase and detected by chemiluminescence (Pierce).

Results

FOXO3 is frequently deleted in human LAC

HD of FOXO3 was detected in 8 of 33 (24.2%) LAC but in none of the LsqCC examined (Fig. 1). Sub-HD was detected in 20 of 33 (60.6%) primary LAC and in 9 of 19 (47.4%) LsqCC (Table 2). The use of several primers within FOXO3 enabled the identification of exon 2 as the primary site of deletion in the tumors examined (Fig. 1C and D). Most deletions included FOXO3 primer sets 6 and 7, which encompass sets 1 to 3, were used in exon 2 and extend into intron 2 (Fig. 1B and D; Table 1). Primer sets 6 and 7, which encompass sets 1 to 3, were used to confirm deletions affecting exon 2 (data not shown). Of note, the qPCR analysis was of synonymous or homologous DNA, which could identify loss of heterozygosity (LOH).

The neareast flanking genes of FOXO3 were also analyzed for deletion to define more specifically the focus of the observed deletions. Although sub-HDs affected these genes (ARMC2 and LACE1) at a high frequency, none of the HDs of FOXO3 extended into either gene (Fig. 1D). Similar results are shown for the sub-HD losses of FOXO3 in the LsqCC. These results identify FOXO3 as a target of deletion in these tumors.

The FOXO3 coding region (exons 2 and 3) was also examined by direct sequence analysis for intragenic mutations in several of the LAC and LsqCC. This alternative mechanism of gene inactivation was not detected in any of the tumors examined. Other mechanisms of gene inactivation in cancer were not addressed in this study.

Evidence in mice suggests that Foxos may act redundantly as suppressors of some cancer types (35). Therefore, as potential additional targets of selective gene loss in NSCLC, we examined other members of the FOXO gene family by qPCR analysis. We observed that, unlike FOXO3, neither FOXO1 nor FOXO4 was deleted in any of the tumors of this study (data not shown).

Decreased FOXO3 mRNA expression in LAC

Real-time reverse transcription-PCR (RT-PCR) was conducted on 17 blindly selected NSCLC, surrounding matched noncancerous tissue, and 10 lung samples of cancer-free donors. Relative expression levels were first measured in normal and adjacent tissue to determine the level of FOXO3 expression in both control sets. Expression of FOXO3 was normalized to GAPDH and was very similar in these two sets of tissues. The mean relative quantitation (RQ) expression values were 0.32 ± 0.08 measured in tumor-free tissue and 0.30 ± 0.06 in adjacent normal tissue (Fig. 2).

Expression was then compared between matched tumor and adjacent normal tissue samples (n = 17). The mean FOXO3 RQ value in the tumor tissue was 0.16 ± 0.02, and there was a trend toward lower FOXO3 expression in tumor tissue compared with matched adjacent normal tissue (P = 0.0829; data not shown). However, when stratified by histology, FOXO3 expression in LAC (n = 11) was found to be significantly lower than expression in matched adjacent normal tissues (P = 0.0292; Fig. 2). The mean RQ values for FOXO3 expression were 0.34 ± 0.08 in adjacent normal tissue and 0.14 ± 0.03 in LAC tissue. FOXO3 expression in LsqCC (n = 5) was not significantly different from matched adjacent normal tissue (P = 0.7150). As described in Materials and Methods, FOXO3 expression was also normalized to three experimentally determined control genes—HPRT1, PES1, and RPLP0—with similarly significant results obtained (data not shown).

FOXO3 protein loss corresponds with gene deletion in LAC

To further investigate the inactivation of FOXO3 in LAC, a sampling of these tumors and noncancerous lung was analyzed for FOXO3 protein expression by immunocytochemistry. Tumor 6784 is shown to stain strongly positive for FOXO3 (Fig. 3A). This is consistent with the qPCR results showing that tumor 6784 has a full complement of FOXO3. Relatively strong nuclear staining of FOXO3 is evident in the noncancerous alveoli (Fig. 3B). In contrast, tumors 6379 and 6498 display evidence of FOXO3 loss, which is consistent with the qPCR results indicating HD of FOXO3 in these tumors (Fig. 3C and D). Heterogeneous staining of FOXO3 is evident in tumor 2621. Areas of both negative and positive staining of FOXO3 were observed on the same slide obtained from this sample (Fig. 3E). This is also consistent with the

Table 2. FOXO3a deletion frequency in NSCLC

<table>
<thead>
<tr>
<th>Tumor</th>
<th>HD</th>
<th>Sub-HD</th>
<th>Total deletion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenocarcinoma</td>
<td>8/33 (24.2%)</td>
<td>20/33 (60.6%)</td>
<td>28/33 (84.8%)</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>0/19</td>
<td>9/19 (47.4%)</td>
<td>9/19 (47.4%)</td>
</tr>
</tbody>
</table>
FOXO3 is transcriptionally activated in cells exposed to BPDE

FOXO3 loss in LAC suggests a role in the suppression of these tumors. As a stress-activated transcription factor, FOXO3 may protect against the tumorigenic effects of carcinogens in the pathogenesis of LAC. BPDE is a carcinogenic metabolite of the polycyclic aromatic hydrocarbon (PAH) benzo[a]pyrene (BaP), which is an environmentally pervasive human lung carcinogen (2–4). We next investigated the functional activation of FOXO3 in cells exposed with BPDE. Using immunofluorescence and confocal microscopy, endogenous FOXO3 was observed to localize from the cytosol to the nucleus, indicating its transcriptional activation within 4 hours of exposure of H1299 cells to 0.7 μmol/L BPDE (Fig. 4A).

The transcriptional activation of FOXO3 in response to BPDE was further investigated by quantitative RT-PCR of a set of FOXO3 effector genes (25–30). For these experiments, FOXO3 expression was restored in A549 cells, which have abnormally low levels of endogenous FOXO3 as a result of gene deletion (25). FOXO3- and empty vector–transfected cells were selected for 3 days with G418 to eliminate cells that failed to transfect. Cells were then treated with 0.7 μmol/L BPDE and harvested 18 hours later. A FOXO3-dependent increase in the expression of GADD45B, BIM, BNIP3, and FASL was observed (Fig. 4B). Each of these FOXO3 effectors has been implicated in FOXO3-mediated stress response involving DNA repair (GADD45) and apoptosis (BIM, BNIP3, and FASL).

FOXO3 stimulates apoptosis in response to BPDE in LAC cells

Two different LAC cell lines expressing low endogenous levels of FOXO3 (A549 and H358) were transfected with FOXO3 or empty vector and selected in G418-containing medium. Under these conditions, wild-type FOXO3 caused a significant decrease in the number of viable cells 1 week following transfection (Fig. 5A). Wild-type FOXO3 is transcriptionally active under these conditions, as we have previously reported, resulting in suppression of cell growth (25). The response to BPDE was investigated by treating the selected cells with increasing concentrations (0, 0.4, or 0.7 μmol/L) of BPDE and harvesting after 18 to 36 hours for cell cycle analysis and after 5 days to determine the effect on relative cell number. Exogenous FOXO3 caused a significant decrease in the relative fraction of surviving cells following exposure to 0.7 μmol/L BPDE (Fig. 5B). In contrast, there was no noticeable FOXO3-dependent change in the cell cycle in response to BPDE (Supplementary Fig. S2). These results suggest that FOXO3 augments the sensitivity of LAC cells to BPDE-induced cytotoxicity.

Because we previously showed that FOXO3 elicited apoptosis in response to NNK-induced DNA damage in LAC cells, we next investigated whether FOXO3 also stimulated apoptosis in response to BPDE (25). Experiments were again carried out as described above, and after 24 hours of exposure to 0.7 μmol/L BPDE, apoptosis was measured by fluorescence-activated cell sorting (FACS) selection and quantitation of Annexin V–phycoerythrin (PE)–stained cells. The results showed a significant increase in apoptosis in FOXO3 compared with control transfectants following BPDE treatment (Fig. 5C and D). This analysis was also conducted on stable FOXO3-expressing clones of A549 cells with similar results (Supplementary Fig. S3). Of note, similar results were obtained from both high and low FOXO3-expressing clones (data not shown). Stable independent clones were isolated by dilution following transfection with FOXO3 and clonal expansion during long-term (several weeks) selection with G418.

The role of caspase activation in BPDE-induced apoptosis was examined next. A marked decrease in BPDE-induced FOXO3-dependent apoptosis was observed when cells were cotreated with 15 μmol/L Z-VAD-FMK, a pan-caspase inhibitor (Fig. 5E). This indicated that FOXO3-dependent apoptosis involved caspase activation. Direct analysis of several caspases by Western blot showed evidence of increased caspase-9, caspase-8, and caspase-7 cleavage activation in FOXO3 relative to control transfectants following treatment with BPDE. These results, together with the RT-PCR results, suggest that FOXO3 stimulates apoptosis involving both intrinsic (FASL–caspase-8) and extrinsic (caspase-9) caspase-dependent apoptotic pathways in response to BPDE. Similar caspase activation was obtained in both A549 (p53-positive) and H358 (p53-negative) LAC cell lines (Supplementary Fig. S4).

Discussion

The results of this study show that FOXO3 is a novel target of somatic HD in early-stage LAC. This is supported by RT-PCR and immunocytochemistry results showing concomitant losses of both FOXO3 mRNA and protein in these tumors. Our immunocytochemistry results revealed heterogeneous
loss of FOXO3 in individual stage I LAC. Loss of FOXO3 in several tumors of this early stage, including heterogeneous loss within individual tumors, suggests that FOXO3 inactivation may play a selective role in this stage of malignancy.

Our results also suggest that FOXO3 loss may play a role in early-stage LSqCC. Although LSqCC and LAC are pathogenetically and phenotypically distinct types of NSCLC, they do share some molecular changes, such as TP53 mutation and loss of the CDKN2 tumor suppressor gene (reviewed in ref. 5).

Our analysis of LSqCC detected a decrease in FOXO3 gene dose of >70% in 26% of the patient samples. Although these losses did not meet our conservative threshold for HD, they nevertheless suggest that FOXO3 loss is also a selective occurrence in the development of this type of NSCLC. This is tempered, however, by our observation that FOXO3 expression levels were relatively normal in the LSqCC examined. These results therefore suggest that FOXO3 loss plays a more significant role in LAC than in LSqCC.

In contrast, FOXO1 and FOXO4 genes were not deleted in any of the NSCLC examined in this study. Foxo1, Foxo3, and Foxo4 knockout mice have an increased susceptibility for the development of specific cancer types, including thymic lymphomas and hemangiomas. This finding has implicated all of the FOXO genes as tumor suppressors (35). However, the absence of FOXO1 and FOXO4 deletions indicates that among these three FOXO genes, FOXO3 is uniquely targeted for deletion in NSCLC.

Several pieces of evidence suggest that the mechanism of FOXO3 inactivation in NSCLC may be causally linked with the structure of the FOXO3 locus and its susceptibility to disruption. Here, we show that FOXO3 HDs in tumors of smokers are specifically located in a region of the gene lying 5′ to exon 3. It has been reported that active regions of the FRA6F fragile site are located within this part of human FOXO3 (36). Fragile sites are inherently prone to breakage and consequently are sensitive to DNA-damaging agents, such as genotoxic carcinogens (37, 38). FRA6F has been implicated as a cause of DNA losses at its location on chromosome 6q22-21 in human cancer (38). LOH at this location also is higher in LAC of smokers compared with those of never smokers (39–41). Interestingly, fragile sites are well conserved among mammals, and the same pattern of FOXO3 deletion was observed in mouse LAC, occurring predominantly in tumors induced by carcinogens (24). The structure of the FOXO3 locus may therefore be prone to carcinogen-induced disruption, resulting in the occurrence of relatively precisely positioned FOXO3 HDs in LAC.

An underlying cause of lung cancer is exposure to PAHs such as BaP, which are among the most environmentally pervasive human lung carcinogens (2). Also a component of cigarette smoke, BaP is metabolically activated by cytochrome P450s to BPDE, a highly DNA-reactive and mutagenic diol epoxide (2, 4). Whereas the effects of such DNA-damaging carcinogens are most noticeable in tumor initiation, their effects continue with exposure throughout tumor development. Consequently, carcinogens, such as PAHs, can exert genotoxic stress at any point in tumor development. Taking this into account, we examined the response of FOXO3 to BPDE by restoring its function in LAC cells that apparently had selectively lost FOXO3 through gene deletion during tumor development. We show that FOXO3 is functionally activated as a transcription factor in LAC cells treated with BPDE, and this activation leads to caspase-dependent apoptosis. In this response, we observed upregulation of three known pro-apoptotic FOXO3 effector genes: FASL, BIM, and BNIP3. We previously reported similar results in LAC cells exposed to...
a DNA-reactive metabolite of NNK, also a human lung carcinogen present in tobacco smoke (25). Thus, FOXO3 increases the sensitivity of LAC cells to the effects of genotoxic lung carcinogens. The stimulation of apoptosis in these cells suggests a role in eliminating carcinogen-damaged cells as a means of suppressing LAC. The loss of this function may then increase the likelihood that LAC will result from carcinogen exposure.

We previously showed that bulky DNA adduct–forming carcinogens (including NNK) induce extensive chromosome instability (CIN) as a causal mechanism in LAC of mice (42, 43). BPDE also forms bulky DNA adducts but was not investigated in these studies. CIN is a characteristic of most cancers (18, 19). It is an increase in the rate of chromosomal defects that is considered to be a necessary source of genetic variation acted on by selection pressures in the development of most sporadic cancers (18, 19). The loss of “caretaker” functions, which protect the genome from damage, has been shown to underlie CIN in cancer (44, 45). Based on our findings, FOXO3 may act as a caretaker whose loss can enable CIN, causing DNA damage to accumulate or persist. Therefore, FOXO3 loss may also contribute to the emergence of CIN in LAC.

Consistent with this role is evidence that FOXO3 contributes to the repair of damaged DNA. A role in repair of UV-damaged DNA has been associated with its upregulation of
GADD45 (27). We have shown that GADD45 is also up-regulated by FOXO3 in response to NNK-damaged (25) and BaP-damaged DNA (Fig. 4). Repair of DNA damage caused by lung carcinogens may be another means by which FOXO3 suppresses LAC and possibly protects against CIN induction.

On stress activation, FOXO function overrides its negative control by EGFR/P38/Akt, resulting in growth arrest or apoptosis. Abnormalities of the EGFR signaling network drive the oncogenesis of LAC and, to a lesser extent, LSqCC (5–10). For example, numerous components of this network have been implicated in LAC, including EGFR and K-ras mutations and Akt overexpression (5–10, 46). FOXOs are immediately downstream of Akt and are directly negatively regulated by Akt under physiologic conditions suitable for growth and proliferation (26, 34). However, stress activation of FOXOs overrides the prosurvival and oncogenic signaling of Akt, resulting in cell cycle arrest or apoptosis (25–34). The frequent deletion of FOXO3 therefore would permit unchecked EGFR/P38/Akt signaling in the face of DNA damage, arguably conferring a selective advantage for LAC development.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank D. Shearer and R. Bruggemann for immunocytochemistry and imaging. Dr. A. Barber for confocal microscopy training, and N. Sheaffer and Dr. D. Stanford for assistance with FACS analysis. We are grateful to the Banner Sun Health Research Institute Brain and Body Donation Program of Sun City, Arizona, for the provision of human biological materials (or specific information, e.g., brain tissue and cerebrospinal fluid). The Brain and Body Donation Program is supported by the National Institute on Aging (P30 AG19630 Arizona Alzheimer’s Disease Core Center), the Arizona Department of Health Services (contract 21002, Arizona Alzheimer’s Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901, and 1001 to the Arizona Parkinson’s Disease Consortium), and the Prescott Family Initiative of the Michael J. Fox Foundation for Parkinson’s Research.

Grant Support

The Joan Scarrangello Foundation to Conquer Lung Cancer.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked ‘advertisement’ in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 11/02/2009; revised 05/05/2010; accepted 05/27/2010; published OnlineFirst 07/13/2010.

References


38. Art MF, Durkin SG, Ragland RL, Glover TW. Common fragile sites as targets for chromosome rearrangements. DNA Repair 2006;5:1126–35.
FOXO3 Encodes a Carcinogen-Activated Transcription Factor Frequently Deleted in Early-Stage Lung Adenocarcinoma

Oliver R. Mikse, Daniel C. Blake, Jr., Nathan R. Jones, et al.

Cancer Res  Published OnlineFirst July 14, 2010.

Updated version  Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-09-4008

Supplementary Material  Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2010/07/12/0008-5472.CAN-09-4008.DC1

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, use this link
http://cancerres.aacrjournals.org/content/early/2010/07/09/0008-5472.CAN-09-4008. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.